Clinical Trial: Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease

U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462455) titled 'Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease' on March 04.

Brief Summary: This study is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, PK, and PD profiles of ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial plans to enroll approximately 24 MASLD participants across four dose cohorts, each consisting of 6 participants who will receive oral ACT500 once daily.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Metabolic Dysfu...